Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
Fertitta L, Bergqvist C, Sarin KY, Plotkin SR, Moertel C, Petersen AK, Cannon A, Berman Y, Pichard DC, Röhl C, Lessing A, Brizion B, Peiffer B, Ravaud P, Tran VT, Armand ML, Moryousef S, Ferkal S, Jannic A, Ezzedine K, Wolkenstein P; Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) international collaboration. Fertitta L, et al. Among authors: moertel c. Br J Dermatol. 2024 Jan 23;190(2):216-225. doi: 10.1093/bjd/ljad397. Br J Dermatol. 2024. PMID: 37877514
The 8th International RASopathies Symposium: Expanding research and care practice through global collaboration and advocacy.
Pierpont EI, Bennett AM, Schoyer L, Stronach B, Anschutz A, Borrie SC, Briggs B, Burkitt-Wright E, Castel P, Cirstea IC, Draaisma F, Ellis M, Fear VS, Frone MN, Flex E, Gelb BD, Green T, Gripp KW, Khoshkhoo S, Kieran MW, Kleemann K, Klein-Tasman BP, Kontaridis MI, Kruszka P, Leoni C, Liu CZ, Merchant N, Magoulas PL, Moertel C, Prada CE, Rauen KA, Roelofs R, Rossignol R, Sevilla C, Sevilla G, Sheedy R, Stieglitz E, Sun D, Tiemens D, White F, Wingbermühle E, Wolf C, Zenker M, Andelfinger G. Pierpont EI, et al. Among authors: moertel c. Am J Med Genet A. 2024 Apr;194(4):e63477. doi: 10.1002/ajmg.a.63477. Epub 2023 Nov 15. Am J Med Genet A. 2024. PMID: 37969032
Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.
Osum SH, Oribamise EI, Corbière SMAS, Taisto M, Jubenville T, Coutts A, Kirstein MN, Fisher J, Moertel C, Du M, Bedwell D, Largaespada DA, Watson AL. Osum SH, et al. Among authors: moertel c. Mol Ther Nucleic Acids. 2023 Jun 26;33:227-239. doi: 10.1016/j.omtn.2023.06.018. eCollection 2023 Sep 12. Mol Ther Nucleic Acids. 2023. PMID: 37520682 Free PMC article.
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Moertel CL, Hirbe AC, Shuhaiber HH, Bielamowicz K, Sidhu A, Viskochil D, Weber MD, Lokku A, Smith LM, Foreman NK, Hajjar FM, McNall-Knapp RY, Weintraub L, Antony R, Franson AT, Meade J, Schiff D, Walbert T, Ambady P, Bota DA, Campen CJ, Kaur G, Klesse LJ, Maraka S, Moots PL, Nevel K, Bornhorst M, Aguilar-Bonilla A, Chagnon S, Dalvi N, Gupta P, Khatib Z, Metrock LK, Nghiemphu PL, Roberts RD, Robison NJ, Sadighi Z, Stapleton S, Babovic-Vuksanovic D, Gershon TR; ReNeu Trial Investigators; ReNeu Study Investigators. Moertel CL, et al. J Clin Oncol. 2024 Nov 8:JCO2401034. doi: 10.1200/JCO.24.01034. Online ahead of print. J Clin Oncol. 2024. PMID: 39514826
CD200 depletion in glioma enhances antitumor immunity and induces tumor rejection.
Raphael I, Mujeeb AA, Ampudia-Mesias E, Sever RE, McClellan B, Frederico SC, Sneiderman CT, Mirji A, Daba A, Puerta-Martinez F, Nisnboym M, Edwards WB, Graner M, Moertel CL, Castro MG, Kohanbash G, Olin MR. Raphael I, et al. Among authors: moertel cl. bioRxiv [Preprint]. 2024 Sep 10:2024.09.08.611922. doi: 10.1101/2024.09.08.611922. bioRxiv. 2024. PMID: 39314283 Free PMC article. Preprint.
The OTX2 Gene Induces Tumor Growth and Triggers Leptomeningeal Metastasis by Regulating the mTORC2 Signaling Pathway in Group 3 Medulloblastomas.
Ampudia-Mesias E, Cameron CS, Yoo E, Kelly M, Anderson SM, Manning R, Abrahante Lloréns JE, Moertel CL, Yim H, Odde DJ, Saydam N, Saydam O. Ampudia-Mesias E, et al. Among authors: moertel cl. Int J Mol Sci. 2024 Apr 17;25(8):4416. doi: 10.3390/ijms25084416. Int J Mol Sci. 2024. PMID: 38674001 Free PMC article.
Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors.
Williams KB, Larsson AT, Keller BJ, Chaney KE, Williams RL, Bhunia MM, Draper GM, Jubenville TA, Hudson WA, Moertel CL, Ratner N, Largaespada DA. Williams KB, et al. Among authors: moertel cl. bioRxiv [Preprint]. 2024 Nov 1:2024.03.25.585959. doi: 10.1101/2024.03.25.585959. bioRxiv. 2024. PMID: 38585724 Free PMC article. Preprint.
MYO5A::FGFR1 represents a novel fusion event in pediatric low-grade glioma.
Galvin RT, Zheng C, Fitzpatrick G, Forster CL, Sandoval-Garcia C, Guillaume D, Elbermawy A, Nelson AC, Özütemiz C, Chen L, Moertel CL. Galvin RT, et al. Among authors: moertel cl. Neurooncol Adv. 2023 Feb 23;5(1):vdad017. doi: 10.1093/noajnl/vdad017. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37025756 Free PMC article. No abstract available.
415 results